Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Rhea-AI Summary

Precision BioSciences announces acceptance of abstracts for poster presentations at the European Society of Gene & Cell Therapy Congress

Positive

• Precision BioSciences has announced that two abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for poster presentations at an upcoming Congress. The abstracts focus on the unique features of ARCUS nucleases and the functional improvement in a mouse model of Duchenne muscular dystrophy (DMD) achieved through ARCUS-mediated excision of the 'hot spot' region of the human dystrophin gene.

Negative

• None.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS^® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that two abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for poster presentations at the upcoming Congress on October 24-27, 2023, in Brussels, Belgium.

Presentation Details:

Title: Unique features of ARCUS nucleases enable high efficiency, targeted gene insertion in vivo
Poster Number: #P641
Presenter: Cassie Gorsuch, VP of Gene Therapy, Precision Biosciences
Date and Time: Wednesday, October 25, 2023, 5:00 PM - 6:15 PM CEST and Thursday, October 26, 2023, 8:30 PM - 9:30 PM CEST
Location: Gare Maritime

Title: ARCUS-mediated excision of the “hot spot” region of the human dystrophin gene results in functional improvement in a mouse model of Duchenne muscular dystrophy (DMD)
Poster Number: Poster #P653
Presenter: Cassie Gorsuch, VP of Gene Therapy, Precision Biosciences
Date and Time: Wednesday, October 25, 2023, 5:00 PM - 6:15 PM CEST and Thursday, October 26, 2023, 8:30 PM - 9:30 PM CEST
Location: Gare Maritime

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS^® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231012210195/en/

Investor and Media Contact:

Mei Burris

Senior Director of Finance and Corporate Controller

Mei.Burris@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

What is Precision BioSciences?

Precision BioSciences is an advanced gene editing company.

What is the ARCUS platform?

The ARCUS platform is Precision BioSciences' novel proprietary platform for in vivo gene editing therapies.

What is the European Society of Gene & Cell Therapy?

The European Society of Gene & Cell Therapy (ESGCT) is an organization that focuses on advancing gene and cell therapy research.

What are the abstracts about?

The abstracts focus on the unique features of ARCUS nucleases and the functional improvement in a mouse model of Duchenne muscular dystrophy achieved through ARCUS-mediated excision of the 'hot spot' region of the human dystrophin gene.

When and where will the poster presentations take place?

The poster presentations will take place on Wednesday, October 25, 2023, from 5:00 PM to 6:15 PM CEST and Thursday, October 26, 2023, from 8:30 PM to 9:30 PM CEST at Gare Maritime in Brussels, Belgium.